Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stapokibart in seasonal allergic rhinitis (PHECDA)
NCT05908032Phase 3Completed
- Sponsor
- Keymed Biosciences
- Start
- Aug 2023
- Primary completion
- Dec 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of stapokibart in seasonal allergic rhinitis (SAR), sponsored by Keymed Biosciences. Started Aug 2023; status: completed.
02
Drugs
stapokibart
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on NCT05908032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05908032.